Abstract
Hepatic stellate cells (HSCs) are the major site of vitamin A (retinol) esterification and subsequent storage as retinyl esters within lipid droplets. However, retinyl esters become depleted in many pathophysiological states, including acute and chronic liver injuries. Recently, using a liver slice culture system as a model of acute liver injury and fibrogenesis, a time-dependent increase and decrease in the apparent formation of the bioactive retinoid all-trans-retinoic acid (atRA) and retinyl palmitate was measured, respectively. This coincided with temporal changes in the gene expression of retinoid-metabolizing enzymes and binding proteins, that preceded HSC activation. However, the underlying mechanisms that promote early changes in retinoid metabolism remain unresolved. We hypothesized that LX-2 cells could be applied to investigate differences in quiescent and activated HSC retinoid metabolism. We demonstrate that the hypermetabolic state of activated stellate cells relative to quiescent stellate cells may be attributed to induction of STRA6, RBP4, and CYP26A1, thereby reducing intracellular concentrations of atRA. We further hypothesized that paracrine and autocrine cytokine signaling regulates HSC vitamin A metabolism in both quiescent and activated cells. In quiescent cells, tumor necrosis factor a dose-dependently downregulated LRAT and CRBP1 mRNA, with EC50 values of 30-50 pg/mL. Likewise, interleukin-1b decreased LRAT and CRBP1 gene expression but with less potency. In activated stellate cells, multiple enzymes were downregulated, suggesting that the full effects of altered hepatic vitamin A metabolism in chronic conditions require both paracrine and autocrine signaling events. Further, this study suggests the potential for cell type-specific autocrine effects in hepatic retinoid signaling.
| Original language | English |
|---|---|
| Pages (from-to) | 442-454 |
| Number of pages | 13 |
| Journal | Drug Metabolism and Disposition |
| Volume | 52 |
| Issue number | 5 |
| DOIs | |
| State | Published - May 1 2024 |
Bibliographical note
Publisher Copyright:© 2024 American Society for Pharmacology and Experimental Therapy (ASPET). All rights reserved.
Funding
This work was supported by National Institutes of Health National Institute of General Medical Sciences [Grant 5R01GM111772-06] (to N.I.) and National Institute of Diabetes and Digestive and Kidney Diseases [Grant 5T32DK007247-42] (to L.C.C.). N.I. is supported in part by the Milo Gibaldi Endowed Chair for the Department of Pharmaceutics.
| Funders | Funder number |
|---|---|
| Department of Chemistry and Division of Medicinal Chemistry and Pharmaceutics | |
| National Institute of General Medical Sciences DP2GM119177 Sophie Dumont National Institute of General Medical Sciences | 5R01GM111772-06 |
| National Institute of Diabetes and Digestive and Kidney Diseases | 5T32DK007247-42 |
ASJC Scopus subject areas
- Pharmacology
- Pharmaceutical Science